Table 1.
Demographics and survival for patients with selected adnexal tumors
| All adnexal | Sweat gland carcinoma | Hidradenocrcinoma | Spiradenocarcinoma | Sclerosing sweat duct tumor (MAC) | Porocarcinoma | Eccrine adenocarcinoma | Sebaceouscarcinoma | |
|---|---|---|---|---|---|---|---|---|
| Incidence (per million persons, 95% CI) | 11.2 (10.811.4) | 4.0 (3.6–4.4) | 2.0 (1.8–2.3) | 0.4 (0.3–0.6) | 2.7 (2.3–3.0) | 2.2 (1.9–2.5) | 1.8 (1.6–2.1) | 18 (17.8–19.5) |
| N | 7591 | 694 | 485 | 117 | 766 | 644 | 567 | 4325 |
| Age [(median, range), years] | 71 (6–104) | 68 (11–99) | 65 (8–100) | 66 (22–99) | 67 (6–103) | 72(20–103) | 69 (15–98) | 73 (9–104) |
| Follow-up [months, median (range)] | 55 (0–501) | 87 (0–501) | 64 (0–435) | 53 (0–280) | 74 (0–377) | 43 (0–204) | 56 (0–251) | 50 (0–454) |
| Gender | ||||||||
| Male [n (%)] | 4240 (55.9) | 376 (54.2) | 277 (57.1) | 54 (46.1) | 327 (42.7) | 364 (56.5) | 285 (50.3) | 2557 (59.1) |
| Female [n (%)] | 3358 (44.2) | 318 (45.8) | 208 (42.9) | 63 (53.8) | 439 (57.3) | 280 (43.5) | 282 (49.7) | 1768 (40.9) |
| Race | ||||||||
| Black [n (%)] | 348 (4.6) | 49 (7.1) | 47 (9.7) | 8 (6.8) | 22 (2.9) | 42 (6.5) | 52 (9.2) | 128 (3.0) |
| White [n (%)] | 6467 (85.2) | 586 (84.4) | 399 (82.3) | 97 (82.9) | 685 (89.4) | 533 (82.8) | 460 (81.1) | 3707 (85.7) |
| Other [n (%)] | 395 (5.2) | 30 (4.3) | 21 (4.3) | 6 (5.1) | 19 (2.5) | 35 (5.4) | 29 (5.1) | 255 (5.9) |
| Survival | ||||||||
| Alive [n, (% of total)] | 446 (58.8) | 321 (46.3) | 273 (56.3) | 65 (55.6) | 562 (73.4) | 414 (64.3) | 389 (68.6) | 2436 (56.3) |
| Dead [n (% of total)] | 3132 (41.2) | 373 (53.7) | 212 (43.7) | 47 (40.2) | 204 (26.6) | 230 (35.7) | 178 (31.4) | 1889 (43.7) |
| Dead 2/2 NMSC [n (% of total)] | 162 (5.1) | 36 (10.2) | 21 (9.9) | 5 (10.6) | 7 (3.4) | 10 (4.3) | 11 (6.2) | 72 (3.8) |
| 2-Year OS (95% CI) | 86.0 (85.1–86.8) | 86.7 (84.2–89.4) | 85.3 (82.1–88.6) | 82.4 (75.5–90.0) | 92.9 (91.1–94.9) | 85.2 (82.3–88.1) | 87.5 (84.7–90.4) | 84.6 (83.5–85.8) |
| 5-Year OS (95% CI) | 71.1 (70.0–72.2) | 73.7 (70.3–77.2) | 72.0 (67.8–76.5) | 68.0 (59.3–78.0) | 82.6 (79.7–85.7) | 69.1 (65.1–73.3) | 76.4 (72.6–80.4) | 68.1 (66.5–69.6) |
| 2-Year DSS (95% CI) | 98.8 (98.6–99.1) | 97.0 (95.7–98.3) | 98.1 (96.9–99.4) | 96.8 (93.4–100) | 99.4 (98.8–100) | 99.6 (99.1–100) | 99.0 (98.1–99.9) | 99.1 (98.7–99.4) |
| 5-Year DSS (95% CI) | 97.8 (97.4–98.2) | 95.4 (93.7–97.1) | 94.6 (92.3–97.0) | 96.8 (93.4–100) | 99.0 (98.3–99.8) | 98.8 (97.8–99.9) | 98.2 (97.0–99.5) | 98.2 (97.7–98.7) |
OS overall survival, DSS disease-specific survival, CI confidence interval